Scientific Director, Bioconjugation Development

This leadership role sets the long-term scientific vision for bioconjugation development, shaping portfolio strategy for next-generation antibody-drug conjugates and related targeted delivery platforms. The incumbent drives innovation in conjugation technologies and linker-payload design while ensuring regulatory credibility and CMC excellence remain central to organizational decision-making. By guiding functional development and aligning strategy with business priorities, the leader impacts both current programs and future platform development.